admin

Nisatol®, a nutraceutical derived from Nigella sativa seed oil standardized to 10% thymoquinone, offers a novel complementary strategy for managing suboptimal blood pressure, particularly in patients with limited response to pharmacological therapy. A recent 2025 multicenter observational pilot study evaluated its effects in a specific population already undergoing standard treatment. Preliminary findings revealed promising trends.

We’re proud to announce that iNatal® and Meloff® and have been selected as finalists at the NutraIngredients Awards Europe 2025. These nominations highlight our ongoing commitment to advancing science-backed solutions in women’s health and microbiome support.
Join us at Vitafoods Europe in Barcelona, Stand 3B6 from May 20–22, and discover these and other innovative products that could represent valuable opportunities for your market.

A new clinical study further supports the efficacy of Gabapral®, a precision psychobiotic containing Bifidobacterium adolescentis PRL2019, in children suffering from Irritable Bowel Syndrome (IBS) with recurrent abdominal pain. Conducted as a multicenter, randomized, double-blind, placebo-controlled trial, the study demonstrated a significant reduction in both the frequency and intensity of abdominal pain. Additionally, children receiving Gabapral® showed improved stool consistency and overall symptom remission compared to the placebo group. These findings reinforce the role of B. adolescentis PRL2019 as a GABA-producing probiotic with potential therapeutic applications in pediatric IBS.

Sophy® is a clinically validated supplement formulated with Berberine Phytosome®, designed to support women with Polycystic Ovary Syndrome (PCOS). A recent pilot, non-interaction, supplement registry study evaluated its safety profile when used alongside various chronic pharmacological therapies, including antiplatelet agents, anticoagulants, antihypertensives, diabetes management drugs, and thyroid medications.
The results confirmed no significant interactions between Sophy® and these medications. Moreover, no adverse effects or tolerability issues were reported, and patient compliance exceeded 96%, reinforcing its safety as a complementary treatment.

Hyperuricemia, characterized by elevated serum uric acid levels, is increasingly recognized as a risk factor for metabolic, renal, and cardiovascular diseases beyond its well-known link to gout. While dietary modifications offer limited reductions in uric acid levels, innovative approaches are needed for effective management.
A recent study demonstrated that Quevir®, based on Quercetin Phytosome®, may offer a safe, well-tolerated, and scientifically supported solution for hyperuricemia.

Kramegin® Vaginal Douche (MD) is a scientifically formulated medical device designed to provide safe and effective intimate hygiene. It combines boric acid, which eliminates harmful microorganisms, with the protective properties of Krameria triandra extract, offering additional benefits. Unlike conventional douches that may disrupt vaginal microbiota, Kramegin® is specifically designed to support vaginal health in cases of infections, post-menstrual cleansing, post-surgical hygiene, and postpartum recovery.

Zantogin® Gel offers a science-backed, natural solution for women navigating the challenges of menopause or vaginal dryness. By harnessing the power of Zanthalene® and other synergistic ingredients, it delivers fast, effective relief and long-term benefits. Whether managing post-menopausal symptoms or seeking enhanced comfort in daily intimate care, Zantogin® Gel empowers women to reclaim their well-being with confidence.

A recent study underscores the effectiveness of Meloff®, revealing significant improvements in overall sleep quality and a pronounced increase in deep sleep duration. With this new research, Meloff® reinforces its role as a groundbreaking, non-addictive alternative to traditional remedies for mild insomnia.
This innovative supplement harnesses the sleep-enhancing benefits of lemon balm and utilizes Phytosome® technology to ensure optimal absorption of its active compounds.

Antibiotics, though essential in combating bacterial infections, often disrupt gut microbiota, leaving patients vulnerable to gastrointestinal complications.
The introduction of Brevicillin®—a probiotic based on Bifidobacterium breve PRL2020 with intrinsic resistance to amoxicillin and amoxicillin-clavulanate—marks a pivotal step in safeguarding gut health during antibiotic therapy.

Sophy® with Berberine Phytosome® offers a superior solution for managing Polycystic Ovary Syndrome (PCOS) by enhancing berberine’s bioavailability and effectively addressing insulin sensitivity, hormonal balance, and lipid profiles.
A recent study shows that berberine outperforms metformin and myo-inositol in improving key PCOS parameters, making Sophy® a potent natural alternative.